What it sells
We use AI to design antibodies for intractable diseases
Business model breakdown
Buyer: who owns the budget?
UnverifiedPharma discovery/R&D and business development leads.
Trigger: what makes them buy now?
Need to reach hard targets and formats (multispecifics) with drug-like properties from the start.
Workflow: what inputs become what output?
Pharma embeds Nabla's AI plus wet-lab design platform in discovery pipelines to design antibodies and biologics; Nabla also develops own molecules for licensing.
Distribution: how it reaches customers
Business-development partnering (bd@nabla.bio).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2020 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.